Tandem Therapeutics
Tandem Therapeutics is developing first-in-class peptide therapeutics that target and treat the extracellular matrix barrier.
Tandem Therapeutics has raised €152k across 1 funding round from 1 investor, most recently a round in Feb 2023. Based in Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€152k
€151,546
Funding rounds
1
Investors
1
distinct backers
Active since
2023-02
latest 2023-02
Funding by year
EUR raised per yearTandem Therapeutics — funding by year — interactive chart.
Data table
| Tandem Therapeutics — funding by year | |
|---|---|
| 2023 | €152k |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-02-24 | Other | €152k | Venture Kick | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData